European Journal of Cancer
Journal Abbreviation: Eur. J. Cancer
ISSN: 0959-8049
eISSN: 1879-0852
Publisher: Elsevier
Publications (133)
Quality of life in rectal cancer patients with or without oxaliplatin in the randomised CAO/ARO/AIO-04 phase 3 trial (2021)
Kosmala R, Fokas E, Flentje M, Sauer R, Liersch T, Graeven U, Fietkau R, et al.
Journal article
Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer (2021)
Schneeweiss A, Michel LL, Möbus V, Tesch H, Klare P, Hahnen E, Denkert C, et al.
Journal article
Surveillance of patients with conjunctival melanoma in German-speaking countries: A multinational survey of the German dermatologic cooperative oncology group (2021)
Wessely A, Steeb T, Berking C, Schlaak M, Heppt M, Alter M, Bayerl C, et al.
Journal article
Prospective evaluation of the prognostic value of immune-related adverse events in patients with non-melanoma solid tumour treated with PD-1/PD-L1 inhibitors alone and in combination with radiotherapy (2020)
Schweizer C, Schubert P, Rutzner S, Eckstein M, Haderlein M, Lettmaier S, Semrau S, et al.
Journal article
Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (2020)
Schmidt M, Degenhardt T, Fasching P, Lueftner D, Mueller V, Thomssen C, Schem C, et al.
Conference contribution
Characteristics and clinical outcome of breast cancer patients with asymptomatic brain metastases (2020)
Laakmann E, Witzel I, Neunhoeffer T, Weide R, Schmidt M, Park-Simon TW, Mobus V, et al.
Conference contribution
Reduction of Serious Adverse Events (SAE) under palbociclib treatment in patients using an interactive eHealth system (2020)
Schmidt M, Degenhardt T, Fasching P, Lüftner D, Müller V, Thomssen C, Schem C, et al.
Journal article
Usefulness of current candidate genetic markers to identify childhood cancer patients at risk for platinum-induced ototoxicity: Results of the European PanCareLIFE cohort study (2020)
Langer T, Clemens E, Broer L, Maier L, Uitterlinden AG, de Vries AC, van Grotel M, et al.
Journal article
Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials (2020)
Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al.
Journal article
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108) (2019)
Klinghammer K, Gauler T, Dietz A, Grünwald V, Stöhlmacher J, Knipping S, Schroeder M, et al.
Journal article